Clinical Trial: Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096869) titled 'Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients' on July 24.

Brief Summary: The main purpose of this study is to evaluate the bioequivalence of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (100 mg, test product) and Abraxane(R) (100 mg, reference product) in breast cancer patients.

Study Start Date: June 26

Study Type: INTERVENTIONAL

Condition: Bioequivalence

Intervention: DRUG: Paclitaxel protein-bound particles for injectable suspension (albumin-bound)

IV infusion, 260 mg/m^2

DRUG: Abraxane(R)

IV infusion, 260 mg/...